Pharmacokinetic Enhancers (Boosters)-Escort for Drugs against Degrading Enzymes and Beyond.

Abstract

Pharmacokinetic enhancers (boosters) are compounds used in combination with a primary therapeutic agent (drug) and are not used for their direct effects on the disease but because they enhance or restore the activity of the primary agent. Hence, in certain cases, they represent an indispensable escort for enzyme-labile drugs. Pharmacokinetic enhancers can exert their activity on different ways. In the most common case, they inhibit enzymes such as human cytochrome P450 enzymes in the liver or other organs and, thereby, block or reduce undesired metabolism and inactivation of the primary drug. In this review, an overview will be given on the therapeutically most important classes of pharmacokinetic enhancers like β-lactamase inhibitors, inhibitors of CYP (cytochrome P450) enzymes in HIV therapy and hepatitis C, boosters for fluoropyrimidine-type anticancer agents, compounds utilized for enabling therapy of Parkinson's disease with levodopa, and others. Inhibitors of efflux pumps in both pathogenic bacteria and tumor cells will be addresses shortly.

• Authors: Jürgen Krauß, Franz Bracher
• Journal: Scientia pharmaceutica (Sci Pharm) Vol. 86 Issue 4 (Sep 27 2018) ISSN: 2218-0532 [Electronic] Switzerland
• PMID: 30262788 (Publication Type: Journal Article, Review)